These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
106 related items for PubMed ID: 23665886
1. Fatal sepsis and systemic inflammatory response syndrome after off-label prasugrel: a case report. Serebruany VL, Kipshidze N, Pershukov IV, Kuliczkowski W, Carnes J, Atar D. Am J Ther; 2014; 21(6):e229-33. PubMed ID: 23665886 [Abstract] [Full Text] [Related]
2. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD. J Am Coll Cardiol; 2014 Jan 28; 63(3):225-32. PubMed ID: 24140678 [Abstract] [Full Text] [Related]
3. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct 28; 18(103):193-5. PubMed ID: 19877380 [Abstract] [Full Text] [Related]
6. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ. J Am Coll Cardiol; 2012 Jun 19; 59(25):2338-43. PubMed ID: 22698488 [Abstract] [Full Text] [Related]
7. Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Serebruany VL. Cardiovasc Revasc Med; 2011 Jun 19; 12(2):94-8. PubMed ID: 21421187 [Abstract] [Full Text] [Related]
8. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ. Thromb Haemost; 2014 Feb 19; 111(2):258-65. PubMed ID: 24154863 [Abstract] [Full Text] [Related]
9. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? Serebruany VL. Fundam Clin Pharmacol; 2009 Aug 19; 23(4):411-7. PubMed ID: 19500152 [Abstract] [Full Text] [Related]
11. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L. Platelets; 2014 Aug 19; 25(7):506-12. PubMed ID: 24245960 [Abstract] [Full Text] [Related]
12. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A. J Am Coll Cardiol; 2014 Mar 25; 63(11):1061-70. PubMed ID: 24486281 [Abstract] [Full Text] [Related]
14. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Eur Heart J; 2006 May 25; 27(10):1166-73. PubMed ID: 16621870 [Abstract] [Full Text] [Related]
15. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A. J Assoc Physicians India; 2013 Feb 25; 61(2):114-6, 126. PubMed ID: 24471250 [Abstract] [Full Text] [Related]
16. Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel. Serebruany VL, Dinicolantonio JJ, Can MM, Goto S. Cardiology; 2013 Feb 25; 124(2):85-90. PubMed ID: 23369842 [Abstract] [Full Text] [Related]
17. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E, JUMBO-TIMI 26 Investigators. Circulation; 2005 Jun 28; 111(25):3366-73. PubMed ID: 15967851 [Abstract] [Full Text] [Related]
18. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, Satler LF, Suddath WO, Pichard AD, Waksman R. Am J Cardiol; 2013 Mar 15; 111(6):841-5. PubMed ID: 23273719 [Abstract] [Full Text] [Related]
19. Switching acute coronary syndrome patients from prasugrel to clopidogrel. Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G. JACC Cardiovasc Interv; 2013 Feb 15; 6(2):158-65. PubMed ID: 23428007 [Abstract] [Full Text] [Related]